These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 19737942)
1. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942 [TBL] [Abstract][Full Text] [Related]
2. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854 [TBL] [Abstract][Full Text] [Related]
3. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477 [TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis. Creytens D; Van Gorp J; Speel EJ; Ferdinande L Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836 [TBL] [Abstract][Full Text] [Related]
6. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100 [TBL] [Abstract][Full Text] [Related]
7. [Clinical value of fluorescence Wang W; Li X; Liu P; Dong Y Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132 [TBL] [Abstract][Full Text] [Related]
8. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases. Sharma AE; Dickson M; Singer S; Hameed MR; Agaram NP Mod Pathol; 2024 Jun; 37(6):100494. PubMed ID: 38621503 [TBL] [Abstract][Full Text] [Related]
9. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. Segura-Sánchez J; González-Cámpora R; Pareja-Megia MJ; García-Escudero A; Galera-Ruiz H; López-Beltrán A Anticancer Res; 2006; 26(6C):4937-42. PubMed ID: 17214366 [TBL] [Abstract][Full Text] [Related]
10. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499 [TBL] [Abstract][Full Text] [Related]
11. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706 [TBL] [Abstract][Full Text] [Related]
12. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology. Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689 [TBL] [Abstract][Full Text] [Related]
13. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748 [TBL] [Abstract][Full Text] [Related]
14. Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH). Creytens D; van Gorp J; Ferdinande L; Speel EJ; Libbrecht L Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):126-33. PubMed ID: 25679065 [TBL] [Abstract][Full Text] [Related]
15. Detection of Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma. He M; Aisner S; Benevenia J; Patterson F; Harrison LE; Hameed M Pathol Res Pract; 2009; 205(6):386-94. PubMed ID: 19186005 [TBL] [Abstract][Full Text] [Related]
17. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861 [TBL] [Abstract][Full Text] [Related]
18. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516 [TBL] [Abstract][Full Text] [Related]
20. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Somaiah N; Tap W Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]